Item Details
Zambia Signs US$213 Million Joint Venture for Vaccine Manufacturing Plant
On 2 November, Zambia’s Industrial Development Corporation and China’s Jijia International Medical Technology signed a joint venture agreement for ZAMVAX, a vaccine manufacturing project valued at approximately US$213 million across two phases. Phase one is estimated at US$24.13 million and will establish a cholera vaccine fill-and-finish facility in Lusaka, with planned capacity of up to 20 million doses annually. The project offers opportunities for pharmaceutical equipment suppliers, packaging companies, cold-chain providers and technical specialists. HPC can support supplier sourcing and international business partnerships.
Get in Touch
We’ll get back to you shortly.